SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-295921
Filing Date
2022-12-01
Accepted
2022-12-01 07:32:32
Documents
14
Period of Report
2022-11-30
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d423715d8k.htm   iXBRL 8-K 27337
2 EX-99.1 d423715dex991.htm EX-99.1 4830
3 EX-99.2 d423715dex992.htm EX-99.2 5631
  Complete submission text file 0001193125-22-295921.txt   168140

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA pstx-20221130.xsd EX-101.SCH 2838
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE pstx-20221130_lab.xml EX-101.LAB 18737
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE pstx-20221130_pre.xml EX-101.PRE 11699
8 EXTRACTED XBRL INSTANCE DOCUMENT d423715d8k_htm.xml XML 3478
Mailing Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121
Business Address 9390 TOWNE CENTRE DRIVE SUITE 200 SAN DIEGO CA 92121 858-779-3100
Poseida Therapeutics, Inc. (Filer) CIK: 0001661460 (see all company filings)

IRS No.: 472846548 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39376 | Film No.: 221437312
SIC: 2836 Biological Products, (No Diagnostic Substances)